Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations

The liposomal amphotericin B (AmB) formulation, AmBisome(®), still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover, the need for...

Descripción completa

Detalles Bibliográficos
Autores principales: Frézard, Frédéric, Aguiar, Marta M. G., Ferreira, Lucas A. M., Ramos, Guilherme S., Santos, Thais T., Borges, Gabriel S. M., Vallejos, Virgínia M. R., De Morais, Helane L. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864876/
https://www.ncbi.nlm.nih.gov/pubmed/36678729
http://dx.doi.org/10.3390/pharmaceutics15010099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864876/
https://www.ncbi.nlm.nih.gov/pubmed/36678729
http://dx.doi.org/10.3390/pharmaceutics15010099

Ejemplares similares